Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tele-IPT vs Tele-Pharmacotherapy for Depression in Breast Cancer
NCT04973930Phase 3Suspended
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of venlafaxine and escitalopram in major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Primary endpoint: Hamilton Depression Rating Scale at 12 weeks. Started Mar 2022; status: suspended.
02
Drugs
venlafaxineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04973930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973930.